CoviCept Therapeutics, LLC (represented by Forbion)
Developing oral antiviral drug therapies to provide treatments against the 2019 novel coronavirus (COVID-19) and other pandemic RNA viruses. Covicept Therapeutics is a San Diego based company developing an oral small molecule drug that inhibits the replication of SARS-CoV-2 and other RNA viruses including Dengue, Chikungunya and Zika. The drug will be tested in the Brazil Phase 2 HALOS trial (2021). Forbion’s Operating Partner John Montana is responsible for CMC and pre-clinical development at Covicept, and Operating Partner Carlo Incerti advises the company on clinical and regulatory matters.
To create a world of bionic vision for those who have lost their sight.
To provide best in class bionic vision restoration systems enabling the blind to regain greater autonomy and improved quality of daily living.
Pixium Vision, created in December 2011, is a bioelectronics and brain machine interface technology company specialized in neuromodulation application whose mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy.
Prima System features a miniaturized and totally wireless sub-retinal PRIMA implant, a pocket computer equipped with breakthrough algorithms, and a pair of glasses which captures the visual scene.
For the novel breakthrough Prima system, the exclusive transfer of the patented technology was granted by Stanford’s University to Pixium Vision to develop and industrialize the PRIMA bionic vision system.
Pixium Vision is currently conducting in France and in the United States, two feasibility clinical trials with PRIMA, for patients with severe vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD), for which there is no treatment available to date.
Sequana Medical is a commercial stage medical device company utilizing its proprietary alfapump® and DSR® (Direct Sodium Removal) technologies to develop innovative treatments for fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. Fluid overload is a frequent complication of many large diseases including advanced liver disease driven by NASH-related cirrhosis and heart failure, with diuretic resistance being widespread.
The alfapump is a unique, fully implanted wireless device that automatically pumps fluid from the abdominal cavity into the bladder, where it is naturally eliminated through urination. DSR is Sequana Medical’s proprietary approach to managing sodium and fluid overload through use of a sodium-free infusate administered into the abdominal cavity.
The alfapump has been granted breakthrough device designation by the U.S. FDA for recurrent or refractory ascites due to liver cirrhosis. Interim data from the ongoing POSEIDON study showed positive outcomes against all primary endpoints and a rapid and persistent clinically important improvement in quality of life. This study is intended to support a future marketing application of the alfapump in the U.S. and Canada. In Europe, the alfapump is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and over 850 alfapump systems have been implanted to date.
Sequana Medical has combined its proven alfapump and proprietary DSR therapy, and is developing the alfapump DSR, a breakthrough approach to fluid overload due to heart failure. RED DESERT, the repeated dose alfapump DSR study in diuretic-resistant heart failure patients has demonstrated that repeated DSR therapy is able to both manage the fluid and sodium balance of these patients as well as restore their diuretic response and improve their cardio-renal status. The SAHARA DESERT study of alfapump DSR in decompensated heart failure patients is ongoing.
Alertgy is a pioneer in 100% non-invasive continuous blood glucose monitoring technology. Through the use of its patented radio frequency sensor Alertgy’s DeepGluco wearable device is able to accurately measure blood glucose in real time, up to 3 times per minute. Most importantly, using our proprietary AI algorithm, DeepGluco can provide invaluable, up to the minute life-saving alerts to the users and their designated HCPs. Unlike other CGMs, we eliminate interstitial lag as well as painful and uncomfortable side effects of patches, needles, and implants. The final DeepGluco form factor will be similar to modern smart watches, available to consumers following FDA approval.
Aleva Neurotherapeutics SA, a company located at the Innovation Park of the Swiss Federal Institute of Technology (EPFL) in Lausanne, is active in development of innovative active implantable devices for Deep Brain Simulation for the treatment of Parkinson’s Disease.
Pulsify Medical develops wearable, flexible and smart ultrasound patches for non-invasive, real time monitoring of critical cardiac physiological parameters, in particular cardiac output.
A spin off from the renowned institutions imec and the University Leuven (both based in Leuven, Belgium), Pulsify is building on unique and protected IP to develop the world's first ultrasound patch that can be industrialised at scale.
The Pulsify cardiac patch is roughly 10x10cm in size and will be attached to the chest of a patient to monitor 24/7 the performance of the heart, in particular the so-called Cardiac Output, and related physiological parameters such as Ejection Fraction and Stroke Volume.
Who will benefit? Patients with for example heart failure, coronary artery disease, structural heart disease, cardiac rhythm management, congenital heart disease, peripheral heart disease, ischemic heart disease, history of myocardial infarction substance/drug abuse, shock, cytotoxicity. These are patients in the hospital ICU's, in the hospital wards and at home.
The benefits include better health outcomes, ease of use (especially in the home environment) and peace of mind, knowing that the patch will warn both patient and physician if the cardiac performance is becoming dangerous.
Currently no appropriate solutions exist in the market: invasive catheters have intrinsic drawbacks (infection/complication risk; inaccuracy; ICU use only), whereas handheld ultrasound probes cannot monitor cardiac performance beyond a spot-measurement. Pulsify Medical’s smart patch will be the only solution able to monitor cardiac output non-invasively, for the long-term, safe, and at lower cost. They will be easy to apply and comfortable for the patient. Pulsify Medical’s patch is thereby truly differentiated from competition.
Sense Neuro Diagnostics is a medical technology company focused on improving outcomes for stroke and brain injury patients through technology innovations that enable faster detection and more effective triage. Sense is developing non-invasive technology to enable continuous, real-time brain injury monitoring as well as rapid detection of traumatic brain injury and important stroke subtypes—ischemic stroke with large vessel occlusion, ischemic stroke without large vessel occlusion, and intracerebral hemorrhage. Learn about the ongoing pivotal trial for continuous monitoring of intracranial hemorrhage, and the recent military contract to accelerate development of a field device on our website or find Sense Neuro Diagnostics on LinkedIn or Twitter @SenseDx.
Spindiag is a spin-off of Hahn-Schickard, one of the world’s leading research institutions for microsystems technology. Based on its patented microfluidic platform “LabDisk”, Spindiag develops an easy-to-use, compact, and automated point-of-care system for the broad, fast, and affordable screening for respiratory pathogens such as SARS-CoV-2 or drug-resistant pathogens.